{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:20:33Z","timestamp":1768551633577,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To validate the observed\/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>This was a retrospective population-based study of stage I\u2013IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed\/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>The study population included 30,051 patients who were treated at 426 hospitals: low observed\/expected ratio (n=304) 23.5% of cases; intermediate observed\/expected ratio (n=92) 57.8% of cases; and high observed\/expected ratio (n=30) 18.7% of cases. Hospitals with high observed\/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed\/expected ratios (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed\/expected ratios to 48.1 months for hospitals with low observed\/expected ratios (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001). Treatment at a hospital with a high observed\/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01\u20131.11, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.05) and low (HR 1.10, 95% CI 1.04\u20131.16, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001) observed\/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78\u20130.93, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68\u20130.81 <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83\u20130.99, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36\u20130.46, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed\/expected ratio.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Ovarian cancer care at a hospital with a high observed\/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed\/expected ratio hospital classification is a potential mechanism for expanded access to expert care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003665","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T18:11:15Z","timestamp":1578679875000},"page":"328-339","source":"Crossref","is-referenced-by-count":20,"title":["A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals"],"prefix":"10.1097","volume":"135","author":[{"given":"Robert E.","family":"Bristow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrios","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica M.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/AOG.0b013e3182922a17","article-title":"Adherence to treatment guidelines for ovarian cancer as a measure of quality of care","volume":"121","author":"Bristow","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jnci\/djt065","article-title":"Disparities in ovarian cancer care quality and survival according to race and socioeconomic status","volume":"105","author":"Bristow","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2014.02.006","article-title":"Reasons for failure to deliver National Comprehensive Cancer Network (NCC)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center","volume":"133","author":"Erickson","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"333","DOI":"10.14423\/SMJ.0000000000000821","article-title":"Population-based analysis of patient age and other disparities in the treatment of ovarian cancer in Central Appalachia and Kentucky","volume":"111","author":"Ore","year":"2018","journal-title":"South Med J"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ejso.2015.01.006","article-title":"Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer","volume":"41","author":"Lee","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2015.09.015","article-title":"Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer","volume":"139","author":"Galvan-Turner","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002164","article-title":"Association of hospital volume and quality of care with survival for ovarian cancer","volume":"130","author":"Wright","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/AOG.0000000000000643","article-title":"Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines","volume":"125","author":"Bristow","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2003.01.061","article-title":"Insurance status and the use of guideline therapy in the treatment of selected cancers","volume":"21","author":"Harlan","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/(SICI)1097-0142(19970815)80:4<816::AID-CNCR21>3.0.CO;2-V","article-title":"The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women","volume":"80","author":"Parham","year":"1997","journal-title":"Cancer"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.11.025","article-title":"Have racial disparities in ovarian cancer increased over time? An analysis of SEER data","volume":"125","author":"Terplan","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2006.08.010","article-title":"Ovarian cancer: patterns of surgical care across the United States","volume":"103","author":"Goff","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2013.12.017","article-title":"High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease","volume":"132","author":"Bristow","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/cncr.22604","article-title":"Predictors of comprehensive surgical treatment in patients with ovarian cancer","volume":"109","author":"Goff","year":"2007","journal-title":"Cancer"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","article-title":"The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm","volume":"118","author":"Bristow","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2013.07.001","article-title":"Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility","volume":"131","author":"Phippen","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2307\/3348969","article-title":"Evaluating the quality of medical care","volume":"44","author":"Donabedian","year":"1966","journal-title":"Milbank Mem Fund Quart"},{"key":"R20-20230711","first-page":"1145","article-title":"The quality of care: how can it be assessed?","volume":"121","author":"Donabedian","year":"1988","journal-title":"JAMA"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R26-20230711","first-page":"95","article-title":"Update of the NCCN ovarian cancer practice guidelines","volume":"11","author":"Morgan","year":"1997","journal-title":"Oncology"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2012.0140","article-title":"Ovarian cancer, version 3.2012","volume":"10","author":"Morgan","year":"2012","journal-title":"J Nat Comp Canc Netw"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.6004\/jnccn.2013.0142","article-title":"Ovarian cancer, version 2.2013","volume":"11","author":"Morgan","year":"2013","journal-title":"J Nat Comp Canc Netw"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2014.03.561","article-title":"Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status","volume":"134","author":"Bristow","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ygyno.2012.12.016","article-title":"Global ovarian cancer health disparities","volume":"129","author":"Chornokur","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2015.04.011","article-title":"Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer","volume":"138","author":"Hodeib","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R38-20230711","doi-asserted-by":"crossref","first-page":"468.e1","DOI":"10.1016\/j.ajog.2014.10.1104","article-title":"Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California","volume":"212","author":"Long","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1056\/NEJMsa1010705","article-title":"Trends in hospital volume and operative mortality for high-risk surgery","volume":"364","author":"Finks","year":"2011","journal-title":"N Engl J Med"},{"key":"R40-20230711","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1245\/s10434-015-4938-9","article-title":"Is it time to centralize ovarian cancer care in the United States?","volume":"23","author":"Cowan","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R41-20230711","first-page":"499","article-title":"The effect of centralization of primary surgery on survival in ovarian cancer patients","volume":"102","author":"Tingulstad","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R42-20230711","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2016.05.025","article-title":"Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival\u2014a population-based cohort study","volume":"142","author":"Dahm-K\u00e4hler","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R44-20230711","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.envres.2017.03.057","article-title":"Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California","volume":"156","author":"Vieira","year":"2017","journal-title":"Environ Res"},{"key":"R45-20230711","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2011.04.047","article-title":"Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center","volume":"122","author":"Bristow","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R46-20230711","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1002\/cncr.24482","article-title":"Race does not impact outcomes for advanced ovarian cancer patients treated with cisplatin\/paclitaxel: an analysis of Gynecologic Oncology Group trials","volume":"115","author":"Farley","year":"2009","journal-title":"Cancer"},{"key":"R47-20230711","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2008.08.013","article-title":"Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer","volume":"111","author":"Terplan","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R48-20230711","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/cncr.25242","article-title":"Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population","volume":"116","author":"Fairfield","year":"2010","journal-title":"Cancer"},{"key":"R49-20230711","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with Medicare claims","volume":"54","author":"Noone","year":"2016","journal-title":"Med Care"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T21:36:56Z","timestamp":1689111416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003665","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}